Urea derivative or pharmacologically acceptable salt thereof

1. A compound of formula (I) or a pharmacologically acceptable salt thereof:

wherein Ar 1 is a phenyl group optionally having substituent(s), a 5-membered aromatic heterocyclic group optionally having substituent(s), a 6-membered aromatic heterocyclic group optionally having substituent(s), or a bicyclic aromatic heterocyclic group having 8 or 9 atoms and optionally having substituent(s);

Ar 2 is a phenyl group optionally having substituent(s) (except for a phenyl group substituted only with halogen atom(s)), a 5-membered aromatic heterocyclic group optionally having substituent(s), a 6-membered aromatic heterocyclic group optionally having substituent(s), or a bicyclic aromatic heterocyclic group having 8 or 9 atoms and optionally having substituent(s);

X is a group selected from the group consisting of the following a), b), and c),

a) an oxygen atom or a sulfur atom,

b) NR 4 , and

c) NOR 4 , wherein,

when X is b) or c), R 4 is a hydrogen atom, a phenyl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), or a C 1 to C 6 alkyl group optionally having substituent(s);

R 1 is a hydrogen atom, a hydroxy group, a C 1 to C 6 alkoxy group optionally having substituent(s), or a C 1 to C 6 alkyl group optionally having substituent(s);

R 2 and R 3 are each independently a hydrogen atom or a C 1 to C 6 alkyl group optionally having substituent(s) or R 2 and R 3 together form a C 2 to C 6 alkylene group; and

each carbon atom marked with an asterisk is an asymmetric carbon atom.

2. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein

Ar 2 is a group selected from the group consisting of the following A1), A2), A3), A4), A5), A6), A7), A8), A9), and A10):

wherein, when Ar 2 is A2), W 1 is a nitrogen atom or CH optionally substituted with a hydrogen atom, with a halogen atom, or with a C 1 to C 6 alkyl group optionally having substituent(s);

when Ar 2 is A2), W 2 is CH or a nitrogen atom;

when Ar 2 is A3), A4), A5), or A6), W 3 is an oxygen atom, a sulfur atom, or NH optionally substituted with a C 1 to C 6 alkyl group;

when Ar 2 is A3), A4), or A6), W 4 is CH or a nitrogen atom;

when Ar 2 is A7), W 5 is CH 2 , an oxygen atom, or a sulfur atom;

when Ar 2 is A7), W 6 is C═O, CH 2 , CF 2 , CHOH, NH optionally substituted with a C 1 to C 6 alkyl group, SO, SO 2 , an oxygen atom, or a sulfur atom;

when Ar 2 is A8), W 7 is NH optionally substituted with a C 1 to C 6 alkyl group or C═O;

when Ar 2 is A8), W 8 is C═O with W 7 being NH optionally substituted with a C 1 to C 6 alkyl group and W 8 is NH optionally substituted with a C 1 to C 6 alkyl group with W 7 being C═O;

when Ar 2 is A10), W 9 is a nitrogen atom or N═O;

when Ar 2 is A1), A2), A3), A4), or A5), R 6 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 alkoxy group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), a C 1 to C 6 alkylsulfanyl group optionally having substituent(s), a C 1 to C 6 alkylsulfinyl group optionally having substituent(s), a C 1 to C 6 alkylsulfonyl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), —CONR 10 R 11 , or —NR 10 R 11 , wherein, when R 6 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), or a C 1 to C 6 alkylsulfonyl group optionally having substituent(s) and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group optionally having substituent(s), or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group;

when Ar 2 is A1), A2), A3), A4), A5), A6), A7), A8), A9), or A10), R 7 is a hydrogen atom, a halogen atom, a C 1 to C 6 alkyl group optionally having substituent(s), or a C 1 to C 6 alkoxy group optionally having substituent(s);

when Ar 2 is A1), A7), A8), or A10), R 8 is a hydrogen atom, a halogen atom, or a C 1 to C 6 alkyl group optionally having substituent(s);

when Ar 2 is A9), R 9 is a hydrogen atom or a C 1 to C 6 alkyl group;

when Ar 2 is A7), m is 0 or 1; and

when Ar 2 is A8), n is 0 or 1;

provided that, when Ar 2 is A1), combinations of the substituents R 6 , R 7 and R 8 exclude a combination of a hydrogen atom and a halogen atom.

3. The compound according to claim 2 or a pharmacologically acceptable salt thereof, wherein

Ar 1 is a group selected from the group consisting of the following B1), B2), B3), B4), B5), B6), B7), B8), B9), B10), B11), and B12):

wherein, when Ar 1 is B2), B3), B7), B8), B10), B11), or B12), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 alkoxy group optionally having substituent(s), a C 3 to C 6 cycloalkyl group optionally having substituent(s), a C 3 to C 6 cycloalkoxy group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), a C 2 to C 6 alkenyl group optionally having substituent(s), a C 2 to C 6 alkynyl group optionally having substituent(s), a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group optionally having substituent(s), a C 1 to C 6 alkylsulfinyl group optionally having substituent(s), a C 1 to C 6 alkylsulfonyl group optionally having substituent(s), —CONR 10 R 11 , —NR 10 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), or a C 1 to C 6 alkylsulfonyl group optionally having substituent(s) and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group optionally having substituent(s), or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group;

when Ar 1 is B1), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 alkoxy group optionally having substituent(s), a C 3 to C 6 cycloalkyl group optionally having substituent(s), a C 3 to C 6 cycloalkoxy group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), a C 2 to C 6 alkenyl group optionally having substituent(s), a C 2 to C 6 alkynyl group optionally having substituent(s), a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group optionally having substituent(s), a C 1 to C 6 alkylsulfinyl group optionally having substituent(s), a C 1 to C 6 alkylsulfonyl group optionally having substituent(s), —CONR 10 R 11 , —NR 10 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group optionally having substituent(s), a C 1 to C 6 acyl group optionally having substituent(s), or a C 1 to C 6 alkylsulfonyl group optionally having substituent(s) and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group optionally having substituent(s), or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group, and R 13 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, or a C 1 to C 6 alkyl group, or R 12 and R 13 may together form a C 3 to C 5 alkylene group or a C 1 to C 2 alkylenedioxy group;

when Ar 1 is B6), R 13 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, or a C 1 to C 6 alkyl group;

when Ar 1 is B9), R 14 and R 15 are each independently a hydrogen atom, a halogen atom, a cyano group, a C 1 to C 6 alkyl group, or a C 1 to C 6 alkoxy group;

when Ar 1 is B2), one of W 10 and W 11 is a nitrogen atom, and the other thereof is CH or a nitrogen atom;

when Ar 1 is B6), B7), B8), B9), B10), B11), or B12), W 12 is an oxygen atom, a sulfur atom, or N—R 16 , wherein, when W 12 is an N—R 16 , R 16 is a hydrogen atom or a C 1 to C 6 alkyl group; and

when Ar 1 is B6), B7), B8), or B9), W 13 is CH or a nitrogen atom.

4. The compound according to claim 3 or a pharmacologically acceptable salt thereof, wherein

when Ar 2 is A1), A2), A3), A4), or A5), R 6 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a halo-C 1 to C 6 alkoxy group, a C 1 to C 6 acyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, a heterocyclic group optionally having substituent(s), —CONR 10 R 11 , or —NR 10 R 11 , wherein, when R 6 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, a C 1 to C 6 acyl group, or a C 1 to C 6 alkylsulfonyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group;

when Ar 2 is A1), A2), A3), A4), A5), A6), A7), A8), A9), or A10), R 7 is a hydrogen atom, a halogen atom, a C 1 to C 6 alkyl group, or a C 1 to C 6 alkoxy group;

when Ar 2 is A1), A7), A8), or A10), R 8 is a hydrogen atom, a halogen atom, or a C 1 to C 6 alkyl group; and

when Ar 2 is A9), R 9 is a hydrogen atom or a C 1 to C 6 alkyl group;

provided that, when Ar 2 is A1), combinations of the substituents R 6 , R 7 and R 8 exclude a combination of a hydrogen atom and a halogen atom.

5. The compound according to claim 4 or a pharmacologically acceptable salt thereof, wherein

R 1 is a hydrogen atom, a hydroxy group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a halo-C 1 to C 6 alkyl group, a hydroxy C 1 to C 6 alkyl group, a carboxy C 1 to C 6 alkyl group, a carbamoyl C 1 to C 6 alkyl group, a mono C 1 to C 6 alkylcarbamoyl C 1 to C 6 alkyl group, a di-C 1 to C 6 alkylcarbamoyl C 1 to C 6 alkyl group, an aminosulfonyl C 1 to C 6 alkyl group, an aromatic heterocyclic C 1 to C 3 alkyl group optionally having substituent(s), or a phenyl C 1 to C 3 alkyl group optionally having substituent(s);

R 2 and R 3 are each independently a hydrogen atom or a C 1 to C 3 alkyl group or together form a C 2 to C 6 alkylene group;

when Ar 1 is B2), B3), B7), B8), B10), B11), or B12), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group, a halo-C 1 to C 6 alkyl group, a hydroxy C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 3 to C 6 cycloalkyl group, a C 3 to C 6 cycloalkoxy group, a C 1 to C 6 acyl group, a C 2 to C 6 alkenyl group, a C 2 to C 6 alkynyl group, a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, —CONR 10 R 11 , —NR 10 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, a C 1 to C 6 acyl group, or a C 1 to C 6 alkylsulfonyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group;

when Ar 1 is B1), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group, a halo-C 1 to C 6 alkyl group, a hydroxy C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 3 to C 6 cycloalkyl group, a C 3 to C 6 cycloalkoxy group, a C 1 to C 6 acyl group, a C 2 to C 6 alkenyl group, a C 2 to C 6 alkynyl group, a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, —CONR 10 R 11 , —NR 1 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, a C 1 to C 6 acyl group, or a C 1 to C 6 alkylsulfonyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 together form a C 3 to C 10 heterocycloalkyl group, and R 13 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, or a C 1 to C 6 alkyl group, or R 12 and R 13 may together form a C 3 to C 5 alkylene group or a C 1 to C 2 alkylenedioxy group; and

X is a group selected from the group consisting of the following a), b), and c),

a) an oxygen atom,

b) NR 4 , and

c) NOR 4 , wherein,

when X is b) or c), R 4 is a hydrogen atom, a hydroxy C 1 to C 6 alkyl group, a phenyl group, a heterocyclic group, or a C 1 to C 6 alkyl group.

6. The compound according to claim 5 or a pharmacologically acceptable salt thereof, wherein

Ar 2 is a group selected from the group consisting of A1), A2a), A3), and A7a):

wherein, when Ar 2 is A2a), W 2 is the same as that defined in claim 2 when Ar 2 is A2);

when Ar 2 is A3), W 4 is the same as that defined in claim 2 when Ar 2 is A3);

when Ar 2 is A7a), W 6 is the same as that defined in claim 2 when Ar 2 is A7);

when Ar 2 is A1), A2a), A3), or A7a), R 7 is the same as that defined in claim 4 when Ar 2 is A1), A2), A3), or A7);

when Ar 2 is A1) or A7a), R 8 is the same as that defined in claim 4 when Ar 2 is A1) or A7);

when Ar 2 is A7a), m is the same as that defined in claim 2 when Ar 2 is A7);

when Ar 2 is A1), A2a), or A3), R 6 is a hydrogen atom, a halogen atom, a cyano group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a halo-C 1 to C 6 alkoxy group, a C 1 to C 6 acyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, —CONR 10 R 11 , or —NR 10 R 11 , wherein, when R 6 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, or a C 1 to C 6 acyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 may together form a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholinyl group; and

when Ar 2 is A3), W 3 is an oxygen atom or a sulfur atom;

provided that, when Ar 2 is A1), combinations of the substituents R 6 , R 7 and R 8 exclude a combination of a hydrogen atom and a halogen atom.

7. The compound according to claim 6 or a pharmacologically acceptable salt thereof, wherein

Ar 1 is a group selected from the group consisting of B1), B2), B6a), B9a), and B9b):

wherein, when Ar 1 is B6a), R 13 is the same as that defined in claim 3 when Ar 1 is B6);

when Ar 1 is B9a) or B9b), R 14 and R 15 are the same as those defined in claim 3 when Ar 1 is B9);

when Ar 1 is B2), W 10 and W 11 are the same as those defined in claim 3 when Ar 1 is B2);

when Ar 1 is B2), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group, a halo-C 1 to C 6 alkyl group, a hydroxy C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 3 to C 6 cycloalkyl group, a C 3 to C 6 cycloalkoxy group, a C 1 to C 6 acyl group, a C 2 to C 6 alkenyl group, a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, —CONR 10 R 11 , —NR 10 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, or a C 1 to C 6 acyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 may together form a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholinyl group;

when Ar 1 is B1), R 12 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a C 1 to C 6 alkyl group, a halo-C 1 to C 6 alkyl group, a hydroxy C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 3 to C 6 cycloalkyl group, a C 3 to C 6 cycloalkoxy group, a C 1 to C 6 acyl group, a C 2 to C 6 alkenyl group, a C 1 to C 6 alkoxycarbonyl group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, —CONR 10 R 11 , —NR 10 R 11 , an aryloxy group, or a heterocyclic group optionally having substituent(s), wherein, when R 12 is —CONR 10 R 11 or —NR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, or a C 1 to C 6 acyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 may together form a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholinyl group, and R 13 is a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, or a C 1 to C 6 alkyl group, or R 12 and R 13 may together form a C 3 to C 5 alkylene group or a C 1 to C 2 alkylenedioxy group; and

when Ar 1 is B6a), B9a), or B9b), W 12 is an oxygen atom or a sulfur atom.

8. The compound according to claim 7 or a pharmacologically acceptable salt thereof, wherein

Ar 2 is a group selected from the group consisting of A1a), A2b), A3a), and A7b):

wherein, when Ar 2 is A1a), R 6 is the same as that defined in claim 6 when Ar 2 is A1);

when Ar 2 is A1a) or A7b), R 8 is the same as that defined in claim 4 when Ar 2 is A1) or A7);

when Ar 2 is A7b), m is the same as that defined in claim 2 when Ar 2 is A7);

R 1 is a hydrogen atom, a hydroxy group, a C 1 to C 3 alkyl group, a C 1 to C 3 alkoxy group, a hydroxy C 1 to C 4 alkyl group, a carboxy C 1 to C 3 alkyl group, a carbamoyl C 1 to C 3 alkyl group, a mono-C 1 to C 2 alkylcarbamoyl C 1 to C 3 alkyl group, or a di-C 1 to C 2 alkylcarbamoyl C 1 to C 3 alkyl group;

R 2 and R 3 are each independently a hydrogen atom or a C 1 to C 3 alkyl group;

when X is b) or c), R 4 is a hydrogen atom, a hydroxy C 1 to C 4 alkyl group, or a C 1 to C 3 alkyl group;

when Ar 2 is A2b) or A3a), R 6a is a C 1 to C 3 alkoxy group;

when Ar 2 is Ala), A2b), A3a), or A7b), R 7 is a hydrogen atom, a fluorine atom, a chlorine atom, or a C 1 to C 3 alkyl group; and

when Ar 2 is A7b), W 6 is C═O, CH 2 , CF 2 , CHOH, or an oxygen atom;

provided that, when Ar 1 is Ala), combinations of the substituents R 6 , R 7 and R 8 exclude a combination of a hydrogen atom and a halogen atom.

9. The compound according to claim 8 or a pharmacologically acceptable salt thereof, wherein

Ar 2 is a group selected from the group consisting of A1a), A2b), and A7c):

wherein, when Ar 2 is A2b), R 6a is the same as that defined in claim 8 when Ar 2 is A2b);

when Ar 2 is A1a) or A7c), R 8 is the same as that defined in claim 4 when Ar 2 is A1) or A7);

when Ar 2 is A7c), m is the same as that defined in claim 8 when Ar 2 is A7b);

when Ar 2 is A1a), R 6 is a hydrogen atom, a fluorine atom, a chlorine atom, a cyano group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a halo-C 1 to C 6 alkoxy group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, or —CONRR 11 , wherein, when R 6 is —CONR 10 R 11 , R 10 is a hydrogen atom, a C 1 to C 6 alkyl group, or a C 1 to C 6 acyl group and R 11 is a hydrogen atom or a C 1 to C 6 alkyl group, or R 10 and R 11 may together form a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholinyl group; and

when Ar 2 is A1a), A2b), or A7c), R 7 is a hydrogen atom, a fluorine atom, or a chlorine atom;

provided that, when Ar 2 is A1a), combinations of the substituents R 6 , R 7 and R 8 exclude a combination of a hydrogen atom and a halogen atom.

10. The compound according to claim 9 or a pharmacologically acceptable salt thereof, wherein

Ar 1 is a group selected from the group consisting of B1), B2), B6b), B9c), and B9d):

wherein R 1 is a hydrogen atom, a hydroxy group, a C 1 to C 3 alkyl group, a C 1 to C 3 alkoxy group, or a hydroxy C 1 to C 4 alkyl group;

when Ar 1 is B1) or B2), R 12 is a hydrogen atom, a fluorine atom, a chlorine atom, a cyano group, a C 1 to C 3 alkyl group, or a C 1 to C 6 alkoxy group;

when Ar 1 is B1) or B6b), R 13 is a hydrogen atom, a hydroxy group, a fluorine atom, or a chlorine atom;

when Ar 1 is B9c) or B9d), R 14 is a hydrogen atom, a fluorine atom, a chlorine atom, a C 1 to C 3 alkyl group, a methoxy group, or an ethoxy group;

when Ar 1 is B9c) or B9d), R 15 is a hydrogen atom, a fluorine atom, or a chlorine atom; and

when Ar 1 is B2), one of W 10 and W 11 is N, and the other thereof is CH.

11. The compound according to claim 10 or a pharmacologically acceptable salt thereof, wherein

Ar 1 is a group selected from the group consisting of B1), B6b), and B9c1):

wherein when Ar 1 is B1), R 12 is the same as that defined in claim 10 when Ar 1 is B1);

when Ar 1 is B1) or B6b), R 13 is the same as that defined in claim 10 when Ar 1 is B1) or B6b); and

when Ar 1 is B9c1), R 14 is the same as that defined in claim 10 when Ar 1 is B9c).

12. The compound according to claim 11 or a pharmacologically acceptable salt thereof, wherein

Ar 2 is a group selected from the group consisting of A1b), A2b), and A7c):

wherein, when Ar 2 is A2b), R 6a is the same as that defined in claim 8 when Ar 2 is A2b);

when Ar 2 is A7c), m is the same as that defined in claim 8 when Ar 2 is A7b);

when Ar 2 is A1b), R 6 is a cyano group, an ethyl group, or a C 1 to C 3 alkoxy group;

R 7 is a fluorine atom or a chlorine atom; and

when Ar 2 is A1b) or A7c), R 8 is a hydrogen atom, a fluorine atom, a chlorine atom, or a C 1 to C 3 alkyl group.

13. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein

the compound represented by the formula (I) is

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-chlorophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(3,4-difluorophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-cyanophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-chlorophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-1-methyl-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*)-4-(4-methoxyphenyl)-1-methyl-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(3-fluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(2-fluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

1-[(3S*,4R*)-4-(2-chloro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-(4-fluorophenyl)-3-[(2S*,4R*)-4-(4-methoxy-2-methylphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(2,5-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(3,5-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(6-fluoro-2,3-dihydrobenzofuran-5-yl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(3-fluoro-5-methoxypyridin-2-yl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*)-4-(5-methoxythiophen-2-yl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-fluorophenyl)-3-[(3S*4R*)-4-(4-methylthiophenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-chlorophenyl)-3-[(3 S *, 4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-cyanophenyl)-3-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-methoxyphenyl)urea,

(−)-1-(5-chlorothiazol-2-yl)-3-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(6-chloropyridin-3-yl)-3-[(3S*4R*)-4-(2,6difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(5-chloropyridin-2-yl)-3-[(3S*4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(benzo[b]thiophen-2-yl)-3-[(3S*,4*R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(5-methylthiophen-2-yl)urea,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*, 5 S*)-4-(4-methoxyphenyl)-5-methyl-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-fluorophenyl)-3-[(3 S *,4R*, 5R*)-4-(4-methoxyphenyl)-5-methyl-2-oxopyrrolidin-3-yl]urea,

(+)-1-(4-chlorophenyl)-3-[(3R*,4S*)-2-oxo-4-phenylpyrrolidin-3-yl]urea,

(±)-trans-1-(4-chlorophenyl)-3-[4-(4-methoxyphenyl)-1-methyl-2-oxopyrrolidin-3-yl]urea,

(±)-trans-1-(4-fluorophenyl)-3-[4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(±)-trans-1-(4-chlorophenyl)-3-[4-(4-methoxyphenyl)-1-methyl-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-phenoxyphenyl)urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3,4-difluorophenyl)urea,

(−)-1-(5-chlorothiophen-2-yl)-3-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(p-tolyl)urea,

(−)-1-[(3S*,4R*)-1-ethyl-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*) 1-(1-hydroxy-2-methylpropan-2-yl)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(±)-trans-1-(4-chlorophenyl)-3-[1-(2-hydroxyethyl)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(+)-trans-1-(4-chlorophenyl)-3-[1-(2-hydroxyethyl)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-trans-1-(4-chlorophenyl)-3-[1-(2-hydroxyethyl)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl)-N-methylacetamide,

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl}propionic acid (isomer A),

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl}-N-methylpropionamide (isomer A),

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl}propionic acid (isomer B),

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl}-N-methylpropionamide (isomer B),

(−)-2-{(3S*,4R*)-3-[3-(4-fluorophenyl)ureido]-4-(4-methoxyphenyl)-2-oxopyrrolidin-1-yl}-N,2-dimethylpropionamide,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-1-methyl-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(2-fluoro-4-methoxyphenyl)-1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(+)-1-(4-fluorophenyl)-3-[(3R*,4S*)-1-methoxy-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-3,5-difluoro-4-{(3R*,4S*)-4-[3-(4-fluorophenyl)ureido]-5-oxopyrrolidin-3-yl}benzamide,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*,Z)-2-(methoxyimino)-4-(4-methoxyphenyl)pyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*,Z)-4-(2-fluoro-4-methoxyphenyl)-2-(methoxyimino)pyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*,Z)-4-(2,6-difluoro-4-methoxyphenyl)-2-(methoxyimino)pyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-(4-fluorophenyl)-3-{(3S*,4R*,Z)-2-[(2-hydroxyethoxy)imino]-4-(4-methoxyphenyl)pyrrolidin-3-yl}urea,

(−)-1-{(3S*,4R*,Z)-4-(2,6-difluoro-4-methoxyphenyl)-2-[(2-hydroxyethoxy)imino]pyrrolidin-3-yl}-3-(4-fluorophenyl)urea,

(−)-1-[(3S*,4R*,Z)-4-(2,6-difluoro-4-methoxyphenyl)-2-(methylimino)pyrrolidin-3-yl]-3-(4-fluorophenyl)urea,

(−)-1-(4-fluorophenyl)-3-[(3S*,4R*,Z)-2-(2-hydroxyimino)-4-(4-methoxyphenyl)pyrrolidin-3-yl]urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3-hydroxy-4-methylphenyl)urea,

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluoro-3-hydroxyphenyl)urea,

(−)-1-(4-chloro-3-hydroxyphenyl)-3-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-(4-cyanophenyl)-3-[(3S*,4R*)-4-(6-fluoro-2,3-dihydrobenzofuran-5-yl)-2-oxopyrrolidin-3-yl]urea,

(−)-1-{(3S*,4R*,Z)-4-(2,6-difluoro-4-methoxyphenyl)-2-[(2-hydroxyethoxy)imino]pyrrolidin-3-yl}-3-(p-tolyl)urea, or

(−)-1-[(3S*,4R*)-4-(2,6-difluoro-4-methoxyphenyl)-1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl]-3-phenylurea.

14. A pharmaceutical composition comprising, as an active ingredient, the compound according to claim 1 or a pharmacologically acceptable salt thereof.

15. A method of agonizing FPRL1 comprising contacting FPRL1 with a compound according to claim 1 or a pharmacologically acceptable salt thereof.

16. A method of treating an inflammatory disease, a chronic airway disease, cancer, septicemia, a circulatory disorder, neuroinflammation, a nervous disorder, pain, aprion disease, amyloidosis, or an immune disorder in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of the compound according to claim 1 or a pharmacologically acceptable salt thereof.

17. The method of claim 16 wherein the immune disorder is an allergic symptom or HIV retrovirus infection.

18. The compound according to claim 1 , wherein the compound represented by the formula (I) is

19. The compound according to claim 1 , wherein the compound represented by the formula (I) is

20. The compound according to claim 1 , wherein the compound represented by the formula (I) is

21. The compound according to claim 1 , wherein the compound represented by the formula (I) is

22. The compound according to claim 1 , wherein the compound represented by the formula (I) is

23. The compound according to claim 1 , wherein the compound represented by the formula (I) is

24. The compound according to claim 1 , wherein the compound represented by the formula (I) is

25. The compound according to claim 1 , wherein the compound represented by the formula (I) is

26. The compound according to claim 1 , wherein the compound represented by the formula (I) is

27. The compound according to claim 1 , wherein the compound represented by the formula (I) is

28. The compound according to claim 1 , wherein the compound represented by the formula (I) is

29. The compound according to claim 1 , wherein the compound represented by the formula (I) is

30. The compound according to claim 11 wherein Ar 1 is B1) and Ar 2 is A1a).

31. The compound according to claim 10 wherein Ar 1 is B2) and Ar 2 is A1a).

32. The compound according to claim 11 wherein Ar 1 is B6b) and Ar 2 is A1a).

33. The compound according to claim 11 wherein Ar 1 is B9c1) and Ar 2 is Ala).

34. The compound according to claim 31 wherein Ar 1 is B1) and Ar 2 is A2).

35. The compound according to claim 8 wherein Ar 1 is B1) and Ar 2 is A3a).

36. The compound according to claim 11 wherein Ar 1 is B1) and Ar 2 is A7c).